FDA Science Board Will Look At “Future Plans” For “Critical Path” At Nov. 5 Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
The meeting is one of several by the agency to discuss the drug development initiative. The final report of FDA’s good manufacturing practices initiative will also be reviewed.